Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029
Status:
Recruiting
Trial end date:
2023-02-10
Target enrollment:
Participant gender:
Summary
A randomized, double-blind, Placebo-controlled, parallel group, dose escalation study to
evaluate the safety, tolerability and pharmacokinetics (PK) of GT20029 following topical
single ascending dose in healthy subjects and multiple ascending dose administration in
subjects with androgenetic alopecia(AGA) or acne